Preventive Care Startup Closes US$1M Pre-Seed Round

Written by

Doctor-Led Hybrid Care Model Secures US$1M to Tackle Singapore’s Chronic Disease Challenge

Singapore, Singapore – April 15, 2026 / PROTOCOL HEALTH PTE. LTD. /

SINGAPORE – PROTOCOL (protocolhealth.sg), a medtech company dedicated to making preventive and chronic care proactive, personal, and grounded in real clinical data, has announced the successful close of US$1 million in pre-seed funding. The round was led by DSG Consumer Partners, with participation from Lightspeed Venture Partners. The capital will be used to grow PROTOCOL’s clinical and operations team, accelerate development of its proprietary health analytics platform, and scale customer acquisition across Singapore.

Singapore faces a striking healthcare paradox: the country is home to one of the world’s longest-lived populations, yet healthy life expectancy trails total lifespan by nearly a decade. One in three residents already lives with hypertension or hyperlipidaemia, and chronic disease rates are expected to continue rising as the population ages. The challenge Singapore now faces is not simply extending lifespan, but improving the quality of those additional years.

Despite significant progress in diagnostics and treatment, most healthcare remains reactive. People seek care only after symptoms appear, at which point conditions are frequently harder and more costly to address. Preventive care does exist, but it is fragmented across multiple providers – bloodwork from one source, prescriptions from another, lifestyle guidance from yet another. No single provider owns the ongoing health relationship with the patient.

PROTOCOL was built to address that gap. By bringing together comprehensive screening, prescription therapies, and personalised coaching within a single integrated care model, the company delivers a continuous, data-driven health relationship rather than isolated episodes of care.

PROTOCOL is redefining what a health check-up can be, transforming it from a one-time event into an ongoing relationship. Operating as a hybrid care model, PROTOCOL combines a physical clinic at 71 Robinson Road, #01-02, Singapore, with a digital-first platform. The company’s approach reflects a core belief that the best health outcomes require flexibility – face-to-face consultations when clinical nuance matters, and seamless digital delivery when convenience and speed are the priority.

Every member receives access to PROTOCOL’s dedicated care team, including doctors, nutritionists, and health coaches, all fully licensed by the Singapore Medical Council and regulated by the Ministry of Health and the Health Sciences Authority. The team goes beyond running tests – they explain what the results mean, what is driving them, and what steps to take in response. The bloodwork is the starting point. The relationship is the product. That care relationship is supported by a suite of clinical services:

Core Health Test

Advanced bloodwork panels tracking over 100 biomarkers across metabolic, hormonal, inflammatory, and organ function categories, with a built-in 6-month re-test to monitor progress and identify changes early.

GLP-1 Weight Management

Clinician-supervised GLP-1 receptor agonist therapy for medically appropriate patients, integrated with ongoing monitoring and dose optimisation.

Testosterone Replacement Therapy (TRT)

Evidence-based TRT protocols for patients with clinically low testosterone, managed through regular bloodwork and physician oversight.

Targeted Supplementation

Clinically validated probiotic and micronutrient protocols prescribed based on individual bloodwork findings rather than generic recommendations.

Every service connects to PROTOCOL’s proprietary health dashboard, currently in beta, which gives members a real-time view of their bloodwork results, trends, and clinical recommendations. New features are being introduced monthly as the platform develops toward becoming each member’s central health record.

PROTOCOL was founded by Mehdi Elaichouni, who was diagnosed with Crohn’s disease at age 17. For years, that diagnosis brought uncertainty and an early understanding that feeling “okay” is not the same as being truly healthy. “What changed everything for me was not chasing fixes, but understanding my body better. Through data, doctors, and consistent lifestyle changes in nutrition, sleep, stress, and training, I learned to be proactive rather than reactive. I have been in remission for years – not by ignoring medicine, but by combining it with clarity and responsibility. That experience shaped PROTOCOL. We believe health should be proactive, personal, and grounded in real data, guided by doctors and coaches who take the time to explain what actually matters. Not fear-driven. Not trend-driven. Just clear, responsible care that helps people stay healthier for longer.”

Mehdi Elaichouni, Founder & CEO, PROTOCOL

Before founding PROTOCOL, Mehdi spent 12 years leading marketing strategy at global firms including WPP, Omnicom, and Publicis, advising Fortune 500 companies and government clients across Asia-Pacific. He also founded Carpe Diem, a group of top-ranked martial arts studios in Singapore and home to Asia’s #1 Jiu-Jitsu team.

“What sets PROTOCOL apart is Mehdi’s conviction that meaningful health outcomes require more than an app. By integrating screening, prescription, and coaching under one roof – both physical and digital – PROTOCOL is building the kind of trusted, recurring health relationship that retains members for life. We see strong parallels to the consumer subscription models we have backed across Asia, and Mehdi brings the rare combination of brand-building expertise and personal mission that the best founders possess.”

Sameer Mehta, Managing Director & Head of Southeast Asia, DSG Consumer Partners

The pre-seed funding will be directed across three priorities: growing the clinical and operations team to meet increasing member demand, accelerating development of PROTOCOL’s proprietary health dashboard and analytics platform with new features launching monthly, and scaling customer acquisition to establish PROTOCOL as Singapore’s leading hybrid preventive care provider.

PROTOCOL is a Singapore-based medtech company making preventive care accessible to everyone. Through a hybrid model that integrates a physical clinic with a digital health platform, PROTOCOL combines advanced bloodwork screening, prescription therapies including GLP-1 and TRT, targeted supplementation, and personalised coaching to deliver data-driven healthcare built around the individual. The company’s proprietary health dashboard provides members with real-time access to their biomarker data, clinical insights, and care plans. Founded in September 2025 and headquartered at 71 Robinson Road, Singapore, PROTOCOL is backed by DSG Consumer Partners and Lightspeed Venture Partners.

According to Bain & Company’s 2024 Asia-Pacific Front Line of Healthcare report, 51% of APAC consumers are now willing to pay more out of pocket for healthcare in exchange for better outcomes and continuity of care – a figure that rises to 58% among Gen Z. PROTOCOL is purpose-built to meet that growing demand.

For more information, visit protocolhealth.sg. Learn more about PROTOCOL’s approach to proactive, personalised healthcare at protocolhealth.sg.

Media Contact

Mehdi Elaichouni

Founder & CEO, PROTOCOL

mehdi@protocolhealth.sg

protocolhealth.sg

Media Assets

High-resolution photos (founder headshot, clinic interior, team) and brand assets are available in the PROTOCOL Media Kit:

https://drive.google.com/drive/folders/106GJ5l6q6elxHO1XVs1yiBVHUB4W4jg-?usp=sharing

All assets are approved for editorial use with attribution to PROTOCOL.